The Food and Drug Administration posted a notice they will host a public meeting on May 4, 2017 focused on autism.
The meeting will be held at the FDA White Oak Campus in Silver Spring, Md. and will be live-streamed online.
In addition, the FDA is soliciting public comments on the issue through July 5, 2017.
SUMMARY AS POSTED:
The Food and Drug Administration (FDA, the Agency, or we) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for autism. Patient-Focused Drug Development is part of FDA's performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism.
The meeting will be held at the FDA White Oak Campus in Silver Spring, Md. and will be live-streamed online.
In addition, the FDA is soliciting public comments on the issue through July 5, 2017.
SUMMARY AS POSTED:
The Food and Drug Administration (FDA, the Agency, or we) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for autism. Patient-Focused Drug Development is part of FDA's performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism.
For the Public Notice on the meeting, and live-streamed online information. Also to submit comments by July 5th, VISIT: https://www.federalregister.gov/documents/2017/03/06/2017-04229/public-meeting-on-patient-focused-drug-development-for-autism-request-for-comments
No comments:
Post a Comment